Substituted 1,2-benzisoxazole compounds and their process of preparation
The chemoselective oxidation of ortho-allyl anilines using meta-chloroperbenzoic acid provides a cost-effective and efficient synthesis of 1,2-benzisoxazole compounds with antipsychotic activity, addressing the inefficiencies of existing methods by offering a straightforward and high-yield process for these compounds.
Patent Information
- Application Number
- PCT/IN2024/050337
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-19
- Filing Date
- 2024-03-29
- Publication Date
- 2024-11-28
AI Technical Summary
Current methods for synthesizing 1,2-benzisoxazole compounds are inefficient due to low yields, multi-step processes, and the use of expensive transition metal catalysts, making them unsuitable for scale-up and cost-effective production, particularly in utilizing the free amine functionality for direct synthesis.
A chemoselective oxidation process using meta-chloroperbenzoic acid to convert ortho-allyl anilines into substituted 1,2-benzisoxazole compounds under mild conditions, providing a straightforward, cost-effective, and high-yield synthesis method.
This method offers a simple, inexpensive, and time-efficient route to functionalized benzisoxazole frameworks with significant antipsychotic activity, suitable for treating neuronal disorders, utilizing readily available starting materials and avoiding the need for expensive catalysts or complex reaction setups.
Smart Images

Figure IMGF000002_0001 
Figure IMGF000004_0001 
Figure IMGF000005_0001
Abstract
Description
[0001]SUBSTITUTED 1,2-BENZISOXAZOLE COMPOUNDS AND THEIR PROCESS OF PREPARATION FIELD OF THE INVENTION The present invention relates to a method of preparation of substituted 1,2-benzisoxazole compounds of Formula I. Further, the present invention relates to 1,2-benzisoxazole compounds of Formula I having antipsychotic activity. More particularly, the present invention relates to a process of preparation of the substituted 1,2 benzisoxazole compounds of Formula (I) through the oxidation reaction of ortho-allyl anilines. Formula (I) BACKGROUND OF THE INVENTION 1,2-benzisoxazoles are privileged molecular frameworks that received widespread applications in the drug discovery arena. At present, there are many marketed drugs bearing a 1,2-benzisoxazole molecular core. These drugs are majorly used as atypical antipsychotics and examples include Paliperidone (in the list of WHO’s essential medicine), Risperidone (brand name Risperdal), Zonisaide (brand name Zonegran), to mention a few. Owing to the diverse biological properties of the benzisoxazole scaffold, chemists have always been interested to devise strategies for the synthesis of such molecules. One of the earliest methodologies for the synthesis of benzisoxazoles was reported by Palermo et al. and utilized a nucleophilic aromatic substitution reaction between benzonitrile and hydroxylamine derivatives (Tetrahedron letters, 1996, 37, 2885). Another widely used reaction in this area involves condensation between 4-hydroxycoumarin and hydroxylamine hydrochloride (Cushman et al., European Journal of Medicinal Chemistry, 2019, 44, 1210). However, both of these methodologies suffer from poor yields and limited scope making them unsuitable for scale-up. Over the years, several other reactions were developed. In 2010, Larrock et al. introduced a synthesis of benzisoxazoles from in-situ generated arynes (Organic Letter, 2010, 12, 1180). This protocol made use of aryne precursors which are highly heat and moisture sensitive. Their preparation involves a tedious, multi-step process and sophisticated reaction setup. Later on, Zhao et al. developed a synthesis of benzisoxazoles using transition metal-catalyzed annulation reactions (Chemical Science, 2014, 5, 1574). This methodology uses expensive transition metal catalysts and also involves multi-step synthesis of the starting materials. Furthermore, the use of transition metal catalysts for the synthesis of bioactive molecules often requires strict procedures for the removal of trace metal impurities which is highly cost-intensive. In 2017, Zhang et al. reported another protocol for the synthesis of benzisoxazoles using a Grignard / Barbier type reaction which employs expensive europium(III)oxide as a ligand and also requires strict anhydrous conditions (Organic Letter, 2017, 19, 1792). From these reactions, it is quite evident that benzisoxazole derivatives can be accessed from diverse organic functional groups like arenes, acetamides, nitriles, oximes, carbonyl compounds, etc. However, to date, there is no report utilizing the free amine functionality for the direct synthesis of benzisoxazoles via an oxidative process. Notably, the free amine functionality is ubiquitously present in various marketed drugs and bioactive molecules. Thus, engaging them in an operationally simple reaction for the synthesis of bio-relevant benzisoxazole scaffold would open potential opportunities for late-stage functionalization of drug molecules. Given the biological significance of benzisoxazole core in medicinal chemistry and drug discovery program, developing straightforward synthesis of functionalized benzoxazole molecules are highly demanding in chemical and pharmaceutical companies. Thus, there remains an unmet need for the design of novel benzisoxazole compounds and development of a method of synthesis of the said compounds, such that the method provides direct synthesis of benzisoxazoles involving simple reactions in a cost effective manner. OBJECTIVES OF THE INVENTION The main objective of the present invention is to provide a process for the preparation of a substituted 1,2-benzisoxazole compound of formula (I). Another objective of the present invention is to provide substituted 1,2-benzisoxazole compounds of formula (I). Still, another objective of the present invention is to provide substituted 1,2-benzisoxazole compounds of formula (I) through the chemoselective oxidation of 2-allyl anilines. Another objective of the present invention is to provide substituuted 1,2-benzisoxazole compounds of formula (I) with high regioselectivity. Yet another objective of the present invention is to provide substituted 1,2-benzisoxazole compound of formula (I) under mild reaction conditions. Yet another objective of the present invention is to provide substituted 1,2-benzisoxazole compound of formula (I) which demonstrate potential biological activity. SUMMARY OF THE INVENTION Accordingly, the present invention provides a process for preparation of a compound of Formula I: Formula I wherein Ar is selected from the group consisting of aryl and heteroaryl, wherein each aryl or heteroaryl is unsubstituted or independently substituted, R is selected from the group consisting of alkyl and cycloalkyl, and R’ is selected from the group consisting of hydrogen and halogen; wherein the process comprises the following steps: (a) adding anhydrous dichloromethane to an ortho-allyl aniline to obtain a solution; (b) cooling the solution obtained in step (a) and adding meta-chloroperbenzoic acid to the solution to obtain a reaction mixture; (c) warming the reaction mixture obtained in step (b) to room temperature and stirring the reaction mixture for a time ranging from 30 to 50 hours to obtain a crude mixture; (d) diluting the crude mixture obtained in step (c) with an organic solvent followed by washing with aqueous sodium bicarbonate solution, wherein the organic solvent forms an organic layer; (e) drying the organic layer obtained from step (d) followed by concentrating to obtain a crude residue; and (f) purifying the crude residue obtained in step (e) using column chromatography with an eluent to obtain the compound of Formula I. Further, the present invention provides a compound of Formua I, or a pharmaceutically acceptable salt thereof; wherein Ar is selected from the group consisting of aryl and heteroaryl, wherein each aryl or heteroaryl is unsubstituted or independently substituted, R is selected from the group consisting of alkyl and cycloalkyl, and R’ is selected from the group consisting of hydrogen and halogen. The method thus provides an inexpensive, easy and less time consuming process for the synthesis of benzisoxazole compounds of the present invention. Furthermore, the present method is operationally simple and employs readily available inexpensive starting materials to make functionally enriched benzisoxazole frameworks. Moreover, benzisoxazole core- based compounds of the present invention exhibit significant antipsychotic activity and are employed for treatment of various types of neuronal disorders. BRIEF DESCRIPTION OF ACCOMPANYING DRAWINGS The present invention will now be described with the help of an accompanying diagram, in which, Figure 1 illustrates OLEX-2 drawing of 2a. Thermal ellipsoids are shown at the 50% probability level. Figure 2a illustrates the1H NMR spectra of 2a. Figure 2b illustrates the13C NMR spectra of 2a. Figure 3a illustrates the1H NMR spectra of 2b. Figure 3b illustrates the13C NMR spectra of 2b. Figure 4a illustrates the1H NMR spectra of 2c. Figure 4b illustrates the13C NMR spectra of 2c. Figure 5a illustrates the1H NMR spectra of 2d. Figure 5b illustrates the13C NMR spectra of 2d. Figure 6a illustrates the1H NMR spectra of 2e. Figure 6b illustrates the13C NMR spectra of 2e. Figure 7a illustrates the1H NMR spectra of 2f. Figure 7b illustrates the13C NMR spectra of 2f. Figure 8a illustrates the1H NMR spectra of 2g. Figure 8b illustrates the13C NMR spectra of 2g. Figure 9a illustrates the1H NMR spectra of 2h. Figure 9b illustrates the13C NMR spectra of 2h. Figure 10a illustrates the1H NMR spectra of 2i. Figure 10b illustrates the13C NMR spectra of 2i. DETAILED DESCRIPTION OF THE INVENTION The terminology used, in the present disclosure, is only for the purpose of explaining a particular embodiment and such terminology shall not be considered to limit the scope of the present disclosure. As used in the present disclosure, the forms "a,” "an," and "the" may be intended to include the plural forms as well, unless the context clearly suggests otherwise. The terms “comprises”, “comprising”, “including”, and “having”, are open ended transitional phrases and therefore specify the presence of stated features, integers, steps, operations, elements, modules, units and / or components, but do not forbid the presence or addition of one or more other features, integers, steps, operations, elements, components, and / or groups thereof. The particular order of steps disclosed in the method and process of the present disclosure are not to be construed as necessarily requiring their performance as described or illustrated. It is also to be understood that additional or alternative steps may be employed. Embodiments are provided so as to thoroughly and fully convey the scope of the present disclosure to the person skilled in the art. Numerous details are set forth, relating to specific components, and methods, to provide a complete understanding of embodiments of the present disclosure. It will be apparent to the person skilled in the art that the details provided in the embodiments should not be construed to limit the scope of the present disclosure. In some embodiments, known processes or well-known apparatus or structures, and well known techniques are not described in detail. Room temperature wherever mentioned is the temperature which is in the range of 20ºC to 30ºC. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by those of ordinary skill in the art to which the invention belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, preferred methods and materials are described. The present invention provides a method of preparation of substituted 1,2-benzisoxazole compounds as well as novel substituted 1,2-benzisoxazole compounds. The method provides an inexpensive, easy and less time consuming process for the synthesis of benzisoxazole compounds of the present invention. A straightforward and operationally simple protocol has been developed in the present invention to prepare the substituted 1,2-benzisoxazole frameworks. The reaction uses meta-chloroperbenzoic acid (mCPBA) as a metal-free inexpensive oxidant for chemoselective oxidation of free amine functionality and regioselectively produces diverse 1,2-benzisoxazoles in high yields. Moreover, the compounds of the present invention exhibit significant antipshycotic activity and is employed for treatment of various types of neuronal disorders. The 1,2-benzisoxazole compounds of the present invention are prepared based on the process disclosed in the present invention. The present invention provides a process for preparation of a compound of Formula I: wherein Ar is selected from the group consisting of aryl and heteroaryl, wherein each aryl or heteroaryl is unsubstituted or independently substituted, R is selected from the group consisting of alkyl and cycloalkyl, and R’ is selected from the group consisting of hydrogen and halogen; wherein the process comprises the following steps (a) adding anhydrous dichloromethane to an ortho-allyl aniline to obtain a solution; (b) cooling the solution obtained in step (a) and adding meta-chloroperbenzoic acid to the solution to obtain a reaction mixture; (c) warming the reaction mixture obtained in step (b) to room temperature and stirring the reaction mixture for a time ranging from 30 to 50 hours to obtain a crude mixture; (d) diluting the crude mixture obtained in step (c) with an organic solvent followed by washing with aqueous sodium bicarbonate solution, wherein the organic solvent forms an organic layer; (e) drying the organic layer obtained from step (d) followed by concentrating to obtain a crude residue; and (f) purifying the crude residue obtained in step (e) using column chromatography with an eluent to obtain the compound of Formula I. In an embodiment of the present invention, in step (b) of the said process, the solution is cooled to a temperature ranging from -5oC to 0oC. In an embodiment of the present invention, in step (b) of the said process, the meta- chloroperbenzoic acid is added to the solution in portions. In an embodiment of the present invention, the organic solvent used for diluting the crude mixture is selected from the group consisting of dichloromethane and ethyl acetate. Preferably, the organic solvent is dichloromethane. In an embodiment of the present invention, the organic layer obtained from step (d) of the said process is dried with a drying agent selected from the group consisting of magnesium sulphate and sodium sulphate. Preferably, the drying agent is magnesium sulphate. In an embodiment of the present invention, the eluent in column chromatography is hexane / ethyl acetate. In an embodiment of the present invention, the process for the preparation of a substituted 1,2-benzisoxazole compound of formula (I) involves the following steps as per Scheme 1: (a) adding anhydrous dichloromethane (3 mL) to ortho-allyl anilines (0.2 mmol) to obtain a solution in a screw-cap reaction tube; (b) placing the reaction tube in an ice bath and adding meta-chloroperbenzoic acid (3.0 equiv) in portions to the solution obtained in step (a) to obtain a reaction mixture; (c) warming the reaction mixture obtained in step (b) to room temperature and stirring the reaction mixture for 36 hours to obtain a crude mixture; (d) diluting the crude mixture obtained in step (c) with dichloromethane followed by washing with aqueous sodium bicarbonate solution, wherein dichloromethane forms an organic layer; (e) drying the organic layer obtained from step (d) using magnesium sulphate followed by concentrating on a rotavap to obtain a crude residue; (f) purifying the crude residue obtained in step (e) using column chromatography on silica gel using hexane / ethyl acetate as eluent to obtain the compound of Formula I. Scheme 1: Synthetic route of substituted 1,2-benzisoxazoles Further, the present invention provides a compound of formula (I). Formula (I) or a pharmaceutically acceptable salt thereof; wherein Ar is selected from the group consisting of aryl and heteroaryl, wherein each aryl or heteroaryl is unsubstituted or independently substituted, R is selected from the group consisting of alkyl and cycloalkyl, and R’ is selected from the group consisting of hydrogen and halogen. The compounds of Formula I are substituted 1,2-benzisoxazole compounds. In an embodiment of the present invention, the Ar in Formula I is selected from the group consisting of aryl and heteroaryl, wherein each aryl or heteroaryl is unsubstituted or independently substituted with a group selected from halogen, and C1-4alkyl, and wherein the R is selected from the group consisting of alkyl and cycloalkyl, wherein the cycloalkyl is unsubstituted or substituted with one to two groups independently selected from C1-4alkyl. In an embodiment of the present invention, the Ar in Formula I is selected from In an embodiment of the present invention, the halogen is selected from the group consisting of fluorine, chlorine, bromine and iodine. Preferably, the halogen is chlorine. In another embodiment of the present invention, the R in Formula I is cyclohexyl substituted with two groups independently selected from C1-4alkyl. In a preferred embodiment, the compounds of Formula I are selected from the following list of compounds or a pharmaceutically acceptable salt thereof: Dimethyl (E)-2-(3-(7-(4- Dimethyl (E)-2-(3-(7- Dimethyl (E)-2-(3-(7-(4- chlorophenyl)benzo[d]isoxazo phenylbenzo[d]isoxazol ethylphenyl)benzo[d]isoxazol l-3-yl)allyl) malonate (2a) e-3-yl)allyl) malonate e-3-yl)allyl) malonate (2c) (2b) Dimethyl (E)-2-(3-(7-(m- Dimethyl(E)-2-(3-(7- Dimethyl (E)-2-(3-(5-chloro- tolyl)benzo[d]isoxazole-3- (thiophen-3-yl) benzo 7-phenylbenzo [d]isoxazol-3- yl)allyl) malonate (2d) [d]isoxazole-3-yl) yl)allyl malonate (2f) malonate (2e) Diethyl (E)-2-(3-(7- phenylbenzo[d]isoxazol-3- Dibenzyl (E)-2-(3-(7- Bis ((1R,2S,5R)-2-isopropyl- yl)allyl)malonate (2g) phenylbenzo[d]isoxazol- 5-methylclohexyl)2-((E)-3-(7- 3-yl)allyl)malonate (2h) phenylbenzo[d] isoxazole-3- yl)allyl) malonate (2i) Further, the present invention provides a pharmaceutical composition comprising a compound of Formula I or a pharmaceutically acceptable salt thereof, along with one or more pharmaceutically acceptable excipients. The pharmaceutical compositions of the present invention comprise a therapeutically effective amount of a compound of the present invention formulated together with one or more pharmaceutically acceptable carriers or excipients. As used herein, the term “pharmaceutically acceptable carrier or excipient” means a non-toxic, inert solid, semi-solid or liquid filler, diluent, encapsulating material or formulation auxiliary of any type. The pharmaceutical compositions of the present invention may contain any conventional non- toxic pharmaceutically-acceptable carriers, adjuvants or vehicles. In some cases, the pH of the formulation may be adjusted with pharmaceutically acceptable acids, bases or buffers to enhance the stability of the formulated compound or its delivery form. A preferred embodiment of the present invention provides the compounds of Formula I which are be used in the treatment of various types of neuronal disorders. The terms “treatment”, “treat”, “treating”, and the like, are meant to include slowing or reversing the progression of a disease or disorder. These terms also include alleviating, ameliorating, attenuating, eliminating, or reducing one or more symptoms of a disease or disorder or condition, even if the disease or disorder or condition is not actually eliminated and even if progression of the disease or disorder or condition is not itself slowed or reversed. In an embodiment, the present invention provides a method of treating and / or preventing a neuropsychiatric illness and / or ameliorating a symptom thereof in a subject in need thereof, comprising administering a therapeutically effective amount of a compound of Formula I to the subject. As explained above, the substituted 1,2-benzisoxazole compounds of Formula I of the present invention are useful in treating or preventing various types of neuronal disorders and neuropsychiatric illness. The present invention therefore provides pharmaceutical composition comprising substituted 1,2-benzisoxazole compounds of Formula I for use in treatment of various types of neuronal disorders. Further provided is the use of a pharmaceutical composition, in the manufacture of a medicament for use in treatment of various types of neuronal disorders. EXAMPLES The following examples are given by way of illustration of the working of the invention in actual practice and therefore should not be construed to limit the scope of the present invention in any way. Example 1: General procedure for the synthesis of 1,2-benzisoxazoles (2a-2i): The ortho-allyl anilines 1 (0.2 mmol) were weighed in a screw-cap reaction tube and anhydrous dichloromethane (3 mL) was added to it. The tube was placed in an ice bath and meta-chloroperbenzoic acid (m-CPBA, 3.0 equiv.) was added to the reaction mixture in portions. The reaction mixture was slowly warmed to room temperature and stirring was continued for 36 h. After completion, the crude mixture was transferred to a separating funnel, diluted with CH2Cl2,and washed with aqueous sodium bicarbonate solution. The organic layer was dried with MgSO4and concentrated on a rotavap. The crude residue was purified using column chromatography on silica gel using hexane / ethyl acetate as eluent to yield pure 1,2-benzisoxazole compound 2. Example 2: Dimethyl (E)-2-(3-(7-(4-chlorophenyl)benzo[d]isoxazol-3-yl)allyl) malonate (2a): The ortho-allyl aniline 1a is reacted as per the process described in Example 1 to yield pure 1,2-benzisoxazole compound 2a. Yellow sticky solid, eluent (15% ethyl acetate in hexane). Yield: 75% (59.8 mg);1H NMR (500 MHz, CDCl3) δ 7.94 – 7.90 (m, 2H), 7.52 (d, J = 8.5 Hz, 1H), 7.47 – 7.44 (m, 2H), 7.42 (d, J = 6.7 Hz, 1H), 7.11 – 7.07 (m, 1H), 6.83 (d, J = 16.0 Hz, 1H), 6.79 – 6.73 (m, 1H), 3.77 (s, 6H), 3.64 (t, J = 7.4 Hz, 1H), 2.97 (t, J = 7.0 Hz, 2H).13C NMR (126 MHz, CDCl3) δ 169.0, 163.2, 156.2, 135.1, 134.4, 134.0, 129.9, 128.9 (2C), 127.7, 124.8, 119.2, 117.9, 116.4, 52.9, 51.1, 32.7. HRMS (ESI-TOF) m / z: [M+H]+. Calcd. for C21H18ClNO5400.0946 found 400.0947. The crystal data and structure refinement for 2a is given in Table 1. The single X-ray quality crystals of 2a were grown from MeCN / Hexane by vapor diffusion technique at room temperature. The crystal data were collected and integrated using a BrukerAxs kappa apex2 CCD diffractometer, with graphite monochromated Mo-Kα radiation. The crystal structure was refined by full-matrix least-squares on the F2 method using the program SHELXL- 2014 / 7. Table 1: Crystal data and structure refinement for 2a Identification code 2a Empirical formula C21 H18 ClNO5 Formula weight 399.81 Temperature 297(2) K Wavelength 1.54178 Å Crystal system Orthorhombic Space group P c a 21 Unit cell dimensions a = 32.893(3) Å α= 90° b = 5.6631(5) Å β= 90° c = 21.301(2) Å ^ = 90°Volume3968.0(6) Å3Z 8Density (calculated)1.339 Mg / m3Absorption coefficient1.982 mm-1F(000) 1664Crystal size0.312 x 0.035 x 0.032 mm3Theta range for data collection 3.395 to 65.998°. Index ranges -32<=h<=38, -2<=k<=6, - 17<=l<=25 Reflections collected 13556 Independent reflections 5772 [R(int) = 0.0782] Completeness to theta = 65.998° 99.0 % Absorption correction Semi-empirical from equivalents Max. and min. transmission 0.7518 and 0.4180 Refinement methodFull-matrix least-squares on F2Data / restraints / parameters 5772 / 1 / 510 Goodness-of-fit on F2 1.009Final R indices [I>2sigma(I)] R1 = 0.1000, wR2 = 0.2530 R indices (all data) R1 = 0.1817, wR2 = 0.3472 Absolute structure parameter 0.25(7) Extinction coefficient n / a Largest diff. peak and hole0.416 and -0.317 e.Å-3Example 3: Dimethyl (E)-2-(3-(7-phenylbenzo[d]isoxazole-3-yl)allyl)malonate (2b): The ortho-allyl aniline 1b is reacted as per the process described in Example 1 to yield pure 1,2-benzisoxazole compound 2b. Beige sticky solid, eluent (14% ethyl acetate in hexane). Yield: 78% (57.0 mg);1H NMR (500 MHz, DMSO-d6) δ 7.99 – 7.97 (m, 2H), 7.82 – 7.81 (m, 1H), 7.64 – 7.63 (m, 1H), 7.52 – 7.49 (m, 2H), 7.45 – 7.41 (m, 1H), 7.22 – 7.19 (m, 1H), 7.14 – 7.10 (m, 1H), 6.84 – 6.78 (m, 1H), 3.94 (t, J = 7.3 Hz, 1H), 3.68 (s, 6H), 2.87 (td, J = 7.3, 1.3 Hz, 2H).13C NMR (126 MHz, DMSO-d6) δ 168.8, 163.2, 155.6, 136.1, 135.0, 129.3, 128.6, 128.3, 128.2, 127.2, 125.0, 119.6, 117.2, 115.8, 52.5, 50.1, 32.0. HRMS (ESI-TOF) m / z: [M+H]+Calcd. for C21H20NO5366.1336 found 366.1339. Example 4: Dimethyl (E)-2-(3-(7-(4-ethylphenyl)benzo[d]isoxazole-3-yl)allyl) malonate (2c): The ortho-allyl aniline 1c is reacted as per the process described in Example 1 to yield pure 1,2-benzisoxazole compound 2c. Brown sticky solid, eluent (15% ethyl acetate in hexane). Yield: 76% (59.8 mg);1H NMR (500 MHz, CDCl3) δ 7.89 – 7.87 (m, 2H), 7.48 (d, J = 8.5 Hz, 1H), 7.42 (d, J = 6.7 Hz, 1H), 7.32 (d, J = 8.2 Hz, 2H), 7.08 (dd, J = 8.7, 6.8 Hz, 1H), 6.83 (d, J = 16.0 Hz, 1H), 6.74 (dt, J = 16.0, 7.1 Hz, 1H), 3.77 (s, 6H), 3.63 (t, J = 7.4 Hz, 1H), 2.98 – 2.95 (m, 2H), 2.71 (q, J = 7.6 Hz, 2H), 1.28 (t, J = 7.6 Hz, 3H).13C NMR (126 MHz, CDCl3) δ 169.0, 163.0, 156.6, 144.7, 134.1, 133.6, 129.1, 128.6, 128.4, 128.3, 125.0, 118.4, 118.1, 116.5, 52.9, 51.2, 32.7, 28.8, 15.7. HRMS (ESI-TOF) m / z: [M+H]+Calcd for C23H24NO5394.1649 found 394.1654. Example 5: Dimethyl (E)-2-(3-(7-(m-tolyl)benzo[d]isoxazole-3-yl)allyl) malonate (2d): The ortho-allyl aniline 1d is reacted as per the process described in Example 1 to yield pure 1,2-benzisoxazole compound 2d. Red oil, eluent (16% ethyl acetate in hexane). Yield: 72% (54.6 mg);1H NMR (500 MHz, CDCl3) δ 7.77 (s, 1H), 7.74 (d, J = 7.8 Hz, 1H), 7.49 (d, J = 8.7 Hz, 1H), 7.42 (d, J = 6.7 Hz, 1H), 7.37 (t, J = 7.6 Hz, 1H), 7.21 (d, J = 7.6 Hz, 1H), 7.09 (dd, J = 8.6, 6.8 Hz, 1H), 6.83 (d, J = 16.0 Hz, 1H), 6.78 – 6.72 (m, 1H), 3.77 (s, 6H), 3.63 (t, J = 7.4 Hz, 1H) , 2.97 (t, J = 7.2 Hz, 2H), 2.44 (s, 3H).13C NMR (126 MHz, CDCl3) δ 169.0, 163.0, 156.5, 138.3, 136.7, 133.7, 129.4, 129.3, 129.2, 128.8, 128.7, 125.8, 124.9, 118.7, 118.0, 116.5, 52.9, 51.2, 32.7, 21.7. HRMS (ESI-TOF) m / z: [M+H]+Calcd. for C22H22NO5380.1492 found 380.1488. Example 6: Dimethyl(E)-2-(3-(7-(thiophen-3-yl)benzo[d]isoxazole-3-yl) malonate (2e): The ortho-allyl aniline 1e is reacted as per the process described in Example 1 to yield pure 1,2-benzisoxazole compound 2e. Red oil, eluent (12% ethyl acetate in hexane). Yield: 68% (50.4 mg);1H NMR (400 MHz, CDCl3) δ 8.32 (s, 1H), 7.69 (d, J = 3.5 Hz, 1H), 7.55 (d, J = 6.3 Hz, 1H), 7.46 – 7.40 (m, 2H), 7.08 – 7.04 (m, 1H), 6.85 – 6.72 (m, 2H), 3.77 (s, 6H), 3.65 – 3.62 (m, 1H), 2.97 (t, J = 6.1 Hz, 2H).13C NMR (101 MHz, CDCl3) δ 169.0, 163.0, 156.1, 137.0, 133.8, 127.2, 126.3, 125.8, 125.3, 124.8, 123.5, 118.3, 118.0, 116.5, 52.9, 51.1, 32.7. HRMS (ESI-TOF) m / z: [M+H]+Calcd. for C19H18NO5S 372.0900 found 372.0904. Example 7: Dimethyl (E)-2-(3-(5-chloro-7-phenylbenzo[d]isoxazol-3-yl)allyl malonate (2f): The ortho-allyl aniline 1f is reacted as per the process described in Example 1 to yield pure 1,2-benzisoxazole compound 2f. Dark red oil, eluent (13% ethyl acetate in hexane). Yield: 70% (56.0 mg);1H NMR (500 MHz, CDCl3) δ 7.93 (d, J = 7.4 Hz, 2H), 7.51 – 7.48 (m, 3H), 7.42 (dd, J = 12.8, 5.4 Hz, 1H), 7.37 (d, J = 1.5 Hz, 1H), 6.79 – 6.72 (m, 2H), 3.78 (s, 6H), 3.63 (t, J = 7.4 Hz, 1H), 2.97 – 2.95 (m, 2H).13C NMR (126 MHz, CDCl3) δ 168.9, 162.7, 155.1, 135.4, 134.4, 130.8, 130.4, 130.2, 129.1, 128.9, 128.7, 117.6, 116.9, 116.5, 53.0, 51.0, 32.7. HRMS (ESI-TOF) m / z: [M+H]+Calcd. for C21H19ClNO5400.0946 found 400.0940. Example 8: Diethyl (E)-2-(3-(7-phenylbenzo[d]isoxazol-3-yl)allyl)malonate (2g): The ortho-allyl anilines 1g is reacted as per the process described in Example 1 to yield pure 1,2-benzisoxazole compound 2g. Brown oil, eluent (10% ethyl acetate in hexane). Yield: 74% (58.2 mg);1H NMR (400 MHz, CDCl3) δ 7.95 (d, J = 7.6 Hz, 2H), 7.52 – 7.48 (m, 2H), 7.48 – 7.43 (m, 2H), 7.39 (t, J = 7.3 Hz, 1H), 7.11 – 7.07 (m, 1H), 6.86 – 6.74 (m, 2H), 4.28 – 4.19 (m, 4H), 3.59 (t, J = 7.4 Hz, 1H), 2.96 (t, J = 6.9 Hz, 2H), 1.30 – 1.26 (m, 6H).13C NMR (101 MHz, CDCl3) δ 168.7, 163.1, 156.5, 136.7, 134.0, 129.1, 128.9, 128.8, 128.7, 128.4, 124.9, 118.8, 117.9, 116.4, 61.9, 51.4, 32.7, 14.2. HRMS (ESI-TOF) m / z: [M+H]+Calcd. for C23H24NO5394.1649 found 394.1642. Example 9: Dibenzyl (E)-2-(3-(7-phenylbenzo[d]isoxazol-3-yl)allyl)malonate (2h): The ortho-allyl anilines 1h is reacted as per the process described in Example 1 to yield pure 1,2-benzisoxazole compound 2h. Brown oil, eluent (12% ethyl acetate in hexane). Yield: 71% (73.5 mg);1H NMR (400 MHz, CDCl3) δ 7.97 (d, J = 7.6 Hz, 2H), 7.49 (dd, J = 16.4, 8.6 Hz, 2H), 7.44 – 7.38 (m, 2H), 7.35 – 7.22 (m, 11H), 7.15 – 7.01 (m, 1H), 6.79 – 6.68 (m, 2H), 5.18 (s, 4H), 3.72 (t, J = 7.4 Hz, 1H), 3.03 – 2.95 (m, 2H).13C NMR (101 MHz, CDCl3) δ 168.3, 163.0, 156.4, 136.7, 135.2, 133.5, 129.0, 128.8 (2C), 128.7 (2C), 128.6, 128.4 (2C), 124.8, 118.9, 118.1, 116.5, 67.6, 51.4, 32.7. HRMS (ESI-TOF) m / z: [M+H]+Calcd. for C33H28NO5518.1962 found 518.1959. Example 10: Bis ((1R,2S,5R)-2-isopropyl-5-methylclohexyl)2-((E)-3-(7- phenylbenzo[d]isoxazole-3-yl)allyl)malonate (2i): The ortho-allyl aniline 1i is reacted as per the process described in Example 1 to yield pure 1,2-benzisoxazole compound 2i. Colourless oil, eluent (3% ethyl acetate in hexane). Yield: 66% (81.0 mg);1H NMR (400 MHz, CDCl3) δ 7.95 (d, J = 7.3 Hz, 2H), 7.52 – 7.45 (m, 3H), 7.44 (d, J = 6.7 Hz, 1H), 7.39 (t, J = 7.3 Hz, 1H), 7.08 (dd, J = 8.6, 6.8 Hz, 1H), 6.88 – 6.71 (m, 2H), 4.79 – 4.71 (m, 2H), 3.58 (t, J = 7.5 Hz, 1H), 3.02 – 2.89 (m, 2H), 2.01 – 1.89 (m, 3H), 1.85 – 1.81 (m, 2H), 1.74 – 1.65 (m, 6H), 1.40-1.37 (m, 3H), 1.05 (dd, J = 17.1, 6.9 Hz, 2H), 1.00 – 0.93 (m, 2H), 0.90 – 0.87 (m, 6H), 0.82 (d, J = 1.9 Hz, 3H), 0.81 (d, J = 2.4 Hz, 3H), 0.74 (d, J = 6.9 Hz, 3H), 0.66 (d, J = 6.9 Hz, 3H).13C NMR (101 MHz, CDCl3) δ 168.3, 161.2, 156.3, 136.8, 134.1, 129.1, 128.8 (2C), 128.7, 128.4, 124.8, 118.8, 117.9, 116.4, 76.0 (2C), 51.8, 47.1, 47.0, 40.9, 40.7, 34.3 (2C), 32.7, 31.5, 26.3, 26.0, 23.4, 23.2, 22.1, 22.0, 21.0, 20.8, 16.2 (2C). HRMS (ESI-TOF) m / z: [M+H]+Calcd. for C39H52NO5614.3840 found 614.3820.
Claims
We claim, 1. A process for preparation of a compound of Formula I,Formula I wherein Ar is selected from the group consisting of aryl and heteroaryl, wherein each aryl or heteroaryl is unsubstituted or independently substituted, R is selected from the group consisting of alkyl and cycloalkyl, and R’ is selected from the group consisting of hydrogen and halogen; wherein the process comprises: (a) adding anhydrous dichloromethane to an ortho-allyl aniline to obtain a solution; (b) cooling the solution obtained in step (a) and adding meta-chloroperbenzoic acid to the solution to obtain a reaction mixture; (c) warming the reaction mixture obtained in step (b) to room temperature and stirring the reaction mixture for a time ranging from 30 to 50 hours to obtain a crude mixture; (d) diluting the crude mixture obtained in step (c) with an organic solvent followed by washing with aqueous sodium bicarbonate solution, wherein the organic solvent forms an organic layer; (e) drying the organic layer obtained from step (d) followed by concentrating to obtain a crude residue; and (f) purifying the crude residue obtained in step (e) using column chromatography with an eluent to obtain the compound of Formula I.
2. The process as claimed in claim 1, wherein in step (b) the solution is cooled to a temperature ranging from -5oC to 0oC.
3. The process as claimed in claim 1, wherein in step (b) the meta-chloroperbenzoic acid is added to the solution in portions.
4. The process as claimed in claim 1, wherein the organic solvent used for diluting the crude mixture is selected from the group consisting of dichloromethane and ethyl acetate.
5. The process as claimed in claim 4, wherein the organic solvent is dichloromethane.
6. The process as claimed in claim 1, wherein the organic layer obtained from step (d) is dried with a drying agent selected from the group consisting of magnesium sulphate and sodium sulphate.
7. The process as claimed in claim 6, wherein the drying agent is magnesium sulphate.
8. The process as claimed in claim 1, wherein the eluent in column chromatography is hexane / ethyl acetate.
9. The process as claimed in claim 1, wherein the process comprises: (a) adding anhydrous dichloromethane to an ortho-allyl aniline to obtain a solution in a screw-cap reaction tube; (b) placing the reaction tube in an ice bath and adding meta-chloroperbenzoic acid in portions to the solution obtained in step (a) to obtain a reaction mixture; (c) warming the reaction mixture obtained in step (b) to room temperature and stirring the reaction mixture for 36 hours to obtain a crude mixture; (d) diluting the crude mixture obtained in step (c) with dichloromethane followed by washing with aqueous sodium bicarbonate solution, wherein dichloromethane forms an organic layer; (e) drying the organic layer obtained from step (d) using magnesium sulphate followed by concentrating on a rotavap to obtain a crude residue; (f) purifying the crude residue obtained in step (e) using column chromatography on silica gel using hexane / ethyl acetate as eluent to obtain the compound of Formula I.
10. A compound of Formula I,Formula (I) or a pharmaceutically acceptable salt thereof; wherein Ar is selected from the group consisting of aryl and heteroaryl, wherein each aryl or heteroaryl is unsubstituted or independently substituted, R is selected from the group consisting of alkyl and cycloalkyl, and R’ is selected from the group consisting of hydrogen and halogen.
11. The compound as claimed in claim 10,wherein the Ar is selected from the group consisting of aryl and heteroaryl, wherein each aryl or heteroaryl is unsubstituted or independently substituted with a group selected from halogen, and C1-4alkyl, and wherein the R is selected from the group consisting of alkyl and cycloalkyl, wherein the cycloalkyl is unsubstituted or substituted with one to two groups independently selected from C1-4alkyl.
12. The compound as claimed in claim 10, wherein the Ar is selected from13. The compound as claimed in claim 10, wherein the halogen is selected from the group consisting of fluorine, chlorine, bromine and iodine.
14. The compound as claimed in claim 10, wherein the halogen is preferably chlorine.
15. The compound as claimed in claim 10, wherein the R is cyclohexyl substituted with two groups independently selected from C1-4 alkyl.
16. The compound as claimed in claim 10, wherein the compound is selected from: Dimethyl (E)-2-(3-(7-(4- Dimethyl (E)-2-(3-(7- Dimethyl (E)-2-(3-(7-(4- chlorophenyl)benzo[d]isoxa phenylbenzo[d]isoxazo ethylphenyl)benzo[d]isoxaz zol-3-yl)allyl) malonate le-3-yl)allyl) malonate ole-3-yl)allyl) malonate Dimethyl (E)-2-(3-(7-(m- Dimethyl(E)-2-(3-(7- Dimethyl (E)-2-(3-(5- tolyl)benzo[d]isoxazole-3- (thiophen-3-yl) benzo chloro-7-phenylbenzo yl)allyl) malonate [d]isoxazole-3-yl) [d]isoxazol-3-yl)allylmalonate malonate Diethyl (E)-2-(3-(7- phenylbenzo[d]isoxazol-3- Dibenzyl (E)-2-(3-(7- Bis ((1R,2S,5R)-2- yl)allyl)malonate phenylbenzo[d]isoxazo isopropyl-5- l-3-yl)allyl)malonate methylclohexyl)2-((E)-3-(7- phenylbenzo[d] isoxazole-3- yl)allyl) malonate or a pharmaceutically acceptable salt thereof.
17. A pharmaceutical composition comprising a compound of Formula I as claimed in claim 10 or a pharmaceutically acceptable salt thereof, along with one or more pharmaceutically acceptable excipients.
18. Use of a compound of Formula I as claimed in claim 10, for treating or preventing neuronal disorders and neuropsychiatric illness.
19. A method of treating and / or preventing a neuropsychiatric illness and / or ameliorating a symptom thereof in a subject in need thereof, comprising administering a therapeutically effective amount of a compound of Formula I as claimed in claim 10 to the subject.
